A clinical study of PCF and FOLFOX4 regimens in the treatment of patients with advanced gastric cancer

Objective To compare the efficacies and toxicities of PFC regimen and FOLFOX4 regimen for treating advanced gastric cancer(AGC). Methods A total of 94 AGC cases was divided into 2 groups.PCF regimen was used in 49 cases(group A),who received PTX 35-50mg/m2 infusion 3 hours,d1,8,15,5-Fu 750mg/m2 continous infusion,d1-5,DDP 20mg/m2 infusion 2 hours,d1-5,every four weeks.FOLFOX4 regimen was used in 45 cases(group B),who received L-OHP 85mg/m2 infusion 2 hours d1 at first,CF 200mg/m2 infusion 2 oursh d1, d2 that was followed by 5-FU 400mg/m2 infusion d1 and d2 and 5-FU 600mg/m2 infusion 22 hours d1 and d2. FOLFOX4 regimen was repearted every 14 days. Results Overall effectiveness rate was 46.9% in group A and 46.7% in group B. Disease control rate was 81.6% in group A and 82.2% in group B.The median survival time was 10.6 months in group A and 9.8 months in group B.One-year survival rate was 35.0% in group A and 33.1% in group B.The common grade Ⅲ/Ⅳ toxicities were bone marrow depression,nausea/vomiting.There were no significant differences in grade alopecia and peripheral nerve toxicity between two groups(P0.05). Conclusion PCF and FOLFOX4 regimens are effective with similar effective-ness and survival rates and tolerable adverse effects as a promising therapy for advanced gastric cancer.